PROPEL BIO PARTNERS
Propel Bio Partners is a new private equity firm targeting high-potential business in the biosciences space. The firm was established during March 2022 by Dr. Leen Kawas and Richard Kayne. Dr. Kawas and Kayne established Propel Bio Partners with the mission to help biosciences businesses that have disruptive technologies further develop those technologies. The firm is especially interested in businesses that are ready to pursue clinical trials or regulatory approval, although promising business... es at other stages might also be considered. When Propel Bio Partners invests in a business, the equity firm will provide both capital and supportive guidance. Starting with Dr. Kawas and Kayne, the firm’s leadership team is a veritable who’s who of the biosciences field. Dr. Leen Kawas comes to the investment firm from Athira Pharma, of which she was both Co-Founder and Chief Executive Officer. At the pharmaceutical company, Dr. Kawas oversaw everything from drug discovery and clinical trials, to operations and financing. She has a doctoral degree in medical research. Richard Kayne has sustained a long career in private equity and venture capital, having established Kayne Anderson Capital Advisors in 1984. The Kayne Anderson firm grew to have billions under management. Richard Kayne has since been personally involved in several promising biosciences startups. A third member of Propel Bio Partners’ leadership team is Dr. Dasom Yoo, whose expertise is in regenerative medicine and stem cells. Dr. Yoo has previously conducted research at Fred Hutchinson Cancer Research Center. She is joining the private equity firm as a Senior Advisor. The trio is complemented by a board room that’s full of leaders from some of the top biosciences companies and high-level government agencies. These advisors have specialized expertise in many areas of research, medicine and business, and it’s Propel Bio Partners’ vision that companies the firm invests in will have access to board members when expertise is needed. Propel Bio Partners maintains offices in Los Angeles, California.
PROPEL BIO PARTNERS
Founded:
2022-03-01
Status:
Active
Technology used in webpage:
Incapsula
Similar Organizations
Advent Life Sciences
Advent Life Sciences is a venture capital firm investing in life sciences businesses.
APEX Ventures
APEX Ventures is a deep-tech and medical-focused venture capital firm.
Base Ventures
Base Ventures is a venture capital company that invests in in seed-stage technology companies.
First In Ventures
First In Ventures is a venture capital firm that invests in biotech companies.
Project Rise
Project Rise is a venture capital firm that invests in tech companies.
Ribbit Capital
Ribbit Capital is a venture capital firm that invests in early-stage companies.
Salkantay Ventures
Salkantay Ventures is a venture capital firm that invests in high-impact technology companies.
Tal Capital
Tal Capital is a venture capital firm that invests in early stage companies.
Current Employees Featured
Leen Kawas Co-Founder and Managing Partner @ Propel Bio Partners
Co-Founder and Managing Partner
2022-03-01
Founder
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2024-02-29 | Achieve Life Science | Propel Bio Partners investment in Post-IPO Equity - Achieve Life Science | 124.2 M USD |
2022-09-05 | Inherent Biosciences | Propel Bio Partners investment in Series A - Inherent Biosciences | N/A |
2022-07-19 | Persephone Biosciences | Propel Bio Partners investment in Seed Round - Persephone Biosciences | 15 M USD |
2021-05-14 | OmniVis | Propel Bio Partners investment in Seed Round - OmniVis | 380 K USD |
More informations about "Propel Bio Partners"
Team - Propel Bio Partners
Team Richard Kayne, MBA General Partner Successful Investor | Entrepreneur | Inventor | Strategist View Bio Leen Kawas, PhD Managing General Partner Entrepreneur | Inventor | …See details»
Propel Bio Partners - Crunchbase Investor Profile
Propel Bio Partners is a new private equity firm targeting high-potential business in the biosciences space. The firm was established during March 2022 by Dr. Leen Kawas and Richard Kayne. Dr. Kawas and Kayne established Propel …See details»
Propel Bio Partners investment portfolio | PitchBook
Jun 29, 2024 Propel Bio Partners's latest investment was on 15-Sep-2022 in Inherent Biosciences, a company within the Biotechnology industry. Data Transparency. Meet our data hygiene team. Discover how our experts ensure …See details»
HOME | Leen Kawas
Propel Bio Partners Launches With Backing of Richard Kayne. The firm, co-led by the Kayne Anderson co-founder, seeks $150 million for its first fund Kayne Anderson Capital Advisors co-founder... Dr. Leen Kawas: A Successful …See details»
Propel Bio Partners: Improving Diversity And …
Nov 7, 2023 Propel Bio Partners invests in companies that improve the quality of life for those with medical conditions, empowering startups with a patient-centric focus for market success.See details»
Propel Bio Partners - Investments, Portfolio & Company Exits
Propel Bio Partners has made 3 diversity investments. Their most recent diversity investment was on Sep 5, 2022, ... Which industries has this organization had the most exits in? Show . …See details»
Propel Bio Partners Commences Operations - leenkawas.com
Co-founded by Richard Kayne of Kayne Anderson and biotech executive, Dr. Leen Kawas, Propel will support entrepreneurs advancing groundbreaking life science technologies and therapies …See details»
Propel Bio Partners - teaserclub.com
Kawas and Kayne established Propel Bio Partners with the mission to help biosciences businesses that have disruptive technologies further develop those technologies. The firm is …See details»
Propel Bio Partners - Portfolio, Partners, Reviews, News
Leen Kawas | Entrepreneur, Inventor, Innovator and Leader | Managing General Partner at Propel Bio Partners. 04.10.2022: Leen Kawas, Ph.D., Accepted into Forbes Business Council: Leen …See details»
Propel Bio Partners Commences Operations - PR Newswire
Mar 18, 2022 Propel Bio Partners LP is a Los Angeles - and Seattle-based global equity investment firm focused on helping entrepreneurial life science companies advance …See details»
Propel Bio Partners - Contacts, Employees, Board Members
Propel Bio Partners has 1 current employee profile, Co-Founder and Managing Partner Leen Kawas. Contacts. Edit Contacts Section. Job Department. Protected Content. Finance and …See details»
News - Propel Bio Partners
Mar 18, 2022 News How To Break The Leadership Glass Ceiling In The Biotech Industry November 5, 2022 Read Article Inherent Biosciences raises Series A funding led by Propel …See details»
Cues and Views: Propel Bio Partners Managing General Partner …
Organization: Propel Bio Partners. Title: Managing General Partner. Pronouns: She/Her/Hers. Alma mater: Washington State University. Languages spoken: Arabic, English and some …See details»
Fundopedia | Propel Bio Partners
Propel Bio Partners builds ecosystems to help founders achieve their vision by advancing groundbreaking technologies and therapies that improve human health.See details»
New life science investment firm Propel debuts | PE Hub
Mar 18, 2022 Propel Bio Partners, a Los Angeles and Seattle-based life science investment firm, has launched. The firm’s co-founders are veteran Richard Kayne and biotech entrepreneur Dr. …See details»
Mike Gibbs - Propel Bio Partners
Neuroscience | Biopharmaceutical Executive | New Product Commercialization | Marketing A Senior Advisor on the Medical and Investment Advisory Board, Mike Gibbs has a long history …See details»
Propel Bio Partners to Raise $150M for Life Science Startups - dot.LA
Mar 18, 2022 Leen Kawas, the Seattle biotech exec who resigned as CEO of Athira Pharma after an investigation found she had altered doctoral research images that helped to form the …See details»
Propel Bio Partners Launches With Backing of Richard Kayne
The firm, co-led by the Kayne Anderson co-founder, seeks $150 million for its first fund Kayne Anderson Capital Advisors co-founder Richard Kayne is helping to launch Propel Bio Partners, …See details»
Inside the futuristic biotech startup Cellares that’s building a cure ...
1 day ago Why New Jersey is a hub for biotech manufacturing. Inside the futuristic biotech startup Cellares that’s building a cure for cancer with $355 million in fundingSee details»
Sam Berry, PhD - Propel Bio Partners
Life Sciences and Bioengineering Translational Research | Competitive Landscape Analysis | Entrepreneurship Consulting Dr. Berry completed his Ph.D. in Applied Bioanalytical Chemistry …See details»